Hepatitis C Articles (HCV)
Back
	Peginterferon Lambda: new interferon in phase 3 now       from Jules: the data reported in these studies below show less side effects compared to peginterferon currently available   EASL 2012 Peginterferon Lambda-1A (Lambda) Compared With Peginterferon Alfa-2A (Alfa) in Treatment- Naive Patients With HCV Genotypes 2 or 3: First SVR24 Results From EMERGE Phase IIb - (04/20/12)   APASL 2012: PEGINTERFERON LAMBDA-1a(LAMBDA) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGINTERFERON ALFA-2a(ALFA-2a) IN PATIENTS WITH CHRONIC HCV INFECTION (G1/2/3/4): EMERGE PHASE 2bTHROUGH WEEK 12RESULTS - (02/27/12)   APASL 2012: SAFETY AND EFFICACY OF PEGINTERFERON LAMBDA-1a (LAMBDA) COMPARED WITH PEGINTERFERON ALFA-2a (ALFA-2a) IN HCV-INFECTED PATIENTS (G1/2/3) WITH COMPENSATED CIRRHOSIS: EMERGE PHASE 2b EFFICACY AND SAFETY RESULTS THROUGH WEEK 12 - (02/27/12)           View Older Articles   Back to Top   www.natap.org